Gregg Gilbert
Stock Analyst at Truist Securities
(2.28)
# 2,613
Out of 4,905 analysts
84
Total ratings
53.7%
Success rate
5.38%
Average return
Main Sectors:
Stocks Rated by Gregg Gilbert
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHT DHT Holdings | Maintains: Buy | $14 → $17 | $10.86 | +56.54% | 2 | Feb 16, 2024 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $31 → $37 | $31.20 | +18.59% | 1 | Jan 4, 2024 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $84 | $47.36 | +77.36% | 9 | Sep 15, 2023 | |
| LLY Eli Lilly and Company | Maintains: Buy | $430 → $525 | $771.71 | -31.97% | 10 | Jul 20, 2023 | |
| EOLS Evolus | Maintains: Buy | $11 → $13 | $9.20 | +41.30% | 2 | Mar 4, 2022 | |
| NVCR NovoCure | Upgrades: Buy | n/a | $16.02 | - | 10 | Jan 20, 2022 | |
| MRK Merck & Co. | Maintains: Buy | $96 → $93 | $79.96 | +16.31% | 8 | Jun 7, 2021 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $38 → $48 | $14.67 | +227.20% | 2 | Feb 2, 2021 | |
| CHRS Coherus Oncology | Initiates: Buy | $26 | $0.88 | +2,851.86% | 1 | Apr 17, 2020 | |
| MTNB Matinas BioPharma Holdings | Initiates: Buy | $150 | $0.96 | +15,525.00% | 1 | Jan 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $93 → $78 | $26.96 | +189.32% | 17 | Aug 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $76 → $78 | $148.60 | -47.51% | 5 | Feb 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $18 | $16.06 | +12.08% | 6 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $175 | $112.87 | +55.05% | 6 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $66 | $189.26 | -65.13% | 4 | Jul 17, 2017 |
DHT Holdings
Feb 16, 2024
Maintains: Buy
Price Target: $14 → $17
Current: $10.86
Upside: +56.54%
Collegium Pharmaceutical
Jan 4, 2024
Maintains: Buy
Price Target: $31 → $37
Current: $31.20
Upside: +18.59%
Bristol-Myers Squibb Company
Sep 15, 2023
Reiterates: Buy
Price Target: $84
Current: $47.36
Upside: +77.36%
Eli Lilly and Company
Jul 20, 2023
Maintains: Buy
Price Target: $430 → $525
Current: $771.71
Upside: -31.97%
Evolus
Mar 4, 2022
Maintains: Buy
Price Target: $11 → $13
Current: $9.20
Upside: +41.30%
NovoCure
Jan 20, 2022
Upgrades: Buy
Price Target: n/a
Current: $16.02
Upside: -
Merck & Co.
Jun 7, 2021
Maintains: Buy
Price Target: $96 → $93
Current: $79.96
Upside: +16.31%
Arcutis Biotherapeutics
Feb 2, 2021
Maintains: Buy
Price Target: $38 → $48
Current: $14.67
Upside: +227.20%
Coherus Oncology
Apr 17, 2020
Initiates: Buy
Price Target: $26
Current: $0.88
Upside: +2,851.86%
Matinas BioPharma Holdings
Jan 24, 2020
Initiates: Buy
Price Target: $150
Current: $0.96
Upside: +15,525.00%
Aug 10, 2018
Downgrades: Hold
Price Target: $93 → $78
Current: $26.96
Upside: +189.32%
Feb 16, 2018
Maintains: Hold
Price Target: $76 → $78
Current: $148.60
Upside: -47.51%
Feb 9, 2018
Maintains: Hold
Price Target: $20 → $18
Current: $16.06
Upside: +12.08%
Aug 9, 2017
Maintains: Buy
Price Target: $178 → $175
Current: $112.87
Upside: +55.05%
Jul 17, 2017
Maintains: Hold
Price Target: $65 → $66
Current: $189.26
Upside: -65.13%